What does MannKind Corp. do?

Jun 22 2025 06:25 PM IST
share
Share Via
MannKind Corporation is a biopharmaceutical company that develops inhaled therapies for diabetes and orphan lung diseases. As of March 2025, it reported net sales of $78 million and a net profit of $13 million, with a market cap of approximately $1.14 billion.
Overview:
MannKind Corporation is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for diabetes and orphan lung diseases, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.

Financial Snapshot:
- Net Sales: 78 Million (Quarterly Results - Mar 2025)
- Net Profit: 13 Million (Quarterly Results - Mar 2025)
- Market cap: USD 1,139.75 Million (Micro Cap)

Key Metrics:
- P/E: 26.00
- Dividend Yield: 0.00%
- Debt Equity: 2.26
- Return on Equity: -86.13%
- Price to Book: -19.44

Contact Details:
- Address: 30930 Russell Ranch Rd Ste 300, WESTLAKE VILLAGE CA: 91362-7379
- Tel: 1 818 6615000
- Website: http://www.mannkindcorp.com
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News